Faron Pharma receives regulators' green light to begin phase I/II trial of promising cancer drug candidate
Investigational new drug applications have been approved in the US and Finland
Company
Faron Pharmaceuticals Limited
LON:FARN
Faron Pharmaceuticals is a global, clinical-stage biopharmaceutical company, focused on creating innovative cancer treatments that leverage the patient’s own immune system. The company’s lead asset bexmarilimab is currently being investigated in Phase I/II clinical trial as a potential therapy for patients with hematological cancers in combination with other standard treatments.
418 stories · page 8 of 21
Faron Pharmaceuticals Oy: Research underlines the potential of lead cancer asset
The article in the journal Molecular Cancer Therapeutics looked at early-stage data, before assessing the potential of bexmarilimab
Faron Pharma to present data from MATINS cancer trial to European melanoma experts
The melanoma cohort is one of the ten advanced treatment-resistant solid tumour types included in Part II of the trial
Faron Pharmaceuticals halts COVID-19 trial as hospital cases drop
The decision was based on a recommendation from the trial’s Independent Data Monitoring Committee (IDMC)
Faron Pharmaceutical heading into 'most important year in its history' says CEO
"Bexmarilimab has the potential to bring the promise of immunotherapy to many more patients"
Faron Pharma identifies possible reason for interferon-beta and steroid clash
The polymorphism, SNP rs9984273, is relatively common, said Faron
Faron Pharmaceuticals will present findings at American Association for Cancer Research annual meeting
The ongoing open-label Phase I/II MATINS clinical trial is investigating the safety and efficacy of bexmarilimab, which is being investigated as a potential monotherapy in patients with solid tumours who have exhausted all other treatment o
Faron Pharmaceuticals agrees funding deal worth up to €30mln
"This financing agreement will notably help us continue to accelerate our ambitious bexmarilimab development programme, which has the potential to bring the promise of immunotherapy to a much broader patient population compared to the relat
Faron Phamraceuticals encouraged by survival data from MATINS cancer trial
Updated results showed 70% of patients receiving treatment had survived nine months
Faron Pharmaceuticals to host virtual R&D day
Faron's new chief medical officer, Dr Marie-Louise Fjällskog, will provide an update on bexmarilimab, the company's wholly-owned novel precision cancer immunotherapy
Faron Pharmaceuticals says Traumakine study shows induction of CD73 molecule prevents death after emergency open aortic surgery
The biopharmaceutical company said its INFORAAA study revealed that up-regulation of CD73 was associated with 100% survival
Faron announces new chief operating officer to catapult cancer immunotherapy development
The new role will include the oversight of academic and industry partnerships, resource prioritisation and allocation, chemistry, manufacturing and controls, supply chain, and driving performance measures
Faron Pharmaceuticals hires new chief medical officer
The newcomer will be tasked with accelerating the company’s clinical development programmes
Faron Pharmaceuticals says biomarker study yields 'exciting' findings
The top-line analysis of the latest patient feedback reveals the bexarilimab ignites a response from those that have not traditionally benefited from current immunotherapy treatments
Proactive news headlines: Faron Pharmaceuticals, Supermarket Income, Nuformix...
A glance at some of the day's highlights from the Proactive Investors newswire
Faron Pharma awarded €3.8mln following Rentschler arbitration
The claim related to a manufacturing agreement for Faron's drug Traumakine
Faron Pharma raises €10.5mln to support two key drug candidates
The share placing was supported by the European Innovation Council
Faron Pharma says study provides 'compelling' evidence cancer drug increases survival in patients with late-stage tumours
"The efficacy and survival data are particularly compelling when you consider the late-stage, treatment-refractory disease patient population and inclusion of nonimmunogenic cold tumours in the trial," said Petri Bono, principal investigato
Faron Pharma set to see the clinical momentum continue after a strong first half
Chief executive Dr Markku Jalkanen said he was "extremely proud" of the progress made over the first half
Faron Pharma: City broker provides its commentary on Covid trial
“We agree with that company, that IFNb (Faron’s formulation and treatment paradigm) is a promising asset in the treatment of coronavirus,” Peel Hunt said in a note to clients